A PDE model for imatinib-treated chronic myelogenous leukemia

Area of Science:

• Mathematical Biology
• Computational Oncology
• Pharmacodynamics

Background:

• Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm.
• Existing models include agent-based and difference equation formulations.
• Imatinib is a targeted therapy for CML.

Purpose of the Study:

• To develop a continuous mathematical model for imatinib-treated CML dynamics.
• To extend previous discrete-time models (agent-based and difference equations).
• To simulate and analyze CML progression and treatment response.

Main Methods:

• Formulation of a system of partial differential equations (PDEs).
• Modeling differentiation and maturation of hematopoietic and leukemic cells.
• Incorporation of imatinib treatment into the PDE model.

Main Results:

• Simulations of the PDE model show qualitative agreement with discrete models.
• Quantitative agreement requires parameter adjustment for imatinib inhibition and degradation rates.
• The model captures key aspects of CML dynamics under treatment.

Conclusions:

• The developed PDE model provides a continuous framework for CML dynamics.
• The model qualitatively reproduces findings from discrete-time models.
• Parameter tuning is crucial for quantitative validation of imatinib treatment effects.